Table 8 Summary of findings for erenumab versus topiramate for migraine prevention

Monthly migraine days

The mean monthly migraine days was −4.02 days

Mean 1.84 days fewer (2.43 fewer to 1.25 fewer)

–

776 (1 RCT)

⨁⨁○○

Low^a,b

Erenumab likely results in a slight reduction in monthly migraine days.

 > 50% reduction in migraine days per month

31 per 100

56 per 100 (48 to 63)

RR 1.78 (1.50 to 2.11)

776 (1 RCT)

⨁⨁○○

Low^a,b

Erenumab likely results in an increase in > 50% reduction in migraine days per month.

Medication discontinuation

39 per 100

11 per 100 (8 to 15)

RR 0.27 (0.20 to 0.37)

776 (1 RCT)

⨁⨁⨁○

Moderate^a

Erenumab likely results in a reduction in medication discontinuation.